Full Report

The numbers behind Vital Farms, Inc.: as-reported financial statements and company metrics for FY2021–FY2025, traced to the source filings, opened with the share-price history those statements have to justify. Every linked figure opens the exact page of the filing it was printed on, with the statement row highlighted. Amounts in US$ thousands unless noted.

Reading notes: All figures are in thousands of US dollars as printed in the filings (per-share and share-count rows excepted), matching each 10-K's '(Amounts in thousands, except share and per share data)' basis. Vital Farms reports on a 52/53-week fiscal year ending the last Sunday of December (e.g., FY2025 ended December 28, 2025). Main statement columns FY2021-FY2025 are each sourced from that year's own Form 10-K (income, balance sheet, revenue breakdown). Cash-flow columns FY2021-FY2023 are sourced from the FY2023 10-K, which prints all three years on the current/restated basis (avoiding the FY2021 10-K's superseded operating-cash-flow classification); FY2024 and FY2025 cash-flow columns are from their own 10-Ks. Revenue breakdown uses the company's reported disaggregation of net revenue into eggs and egg-related products vs. butter and butter-related products.

Share Price — Full Available History — 6 Years

The stock closed at $12.95 on Jul 10, 2026 — down 63% over the window shown (-15.5% a year), trading between $8.17 and $52.41. At that close the stock trades at 9.0× FY2025 diluted EPS as reported below.

Source: market price feed, weekly closes, sampled from 1,492 source observations, Jul 2020–Jul 2026. Price return only, excludes dividends.

FY2025 at a Glance

Source: FY2025 consolidated statements [1] [2] [3] [4]. Click any linked figure to open the filing page with the row highlighted.

Net Revenue by Product Category

Net Revenue by Product Category	FY2021	FY2022	FY2023	FY2024	FY2025
Eggs and egg-related products	239,967	339,214	449,045	580,954	733,176
Butter and butter-related products	20,934	22,836	22,812	25,353	26,268
Net revenue	260,901	362,050	471,857	606,307	759,444
Net revenue growth, derived	—	+38.8%	+30.3%	+28.5%	+25.3%

Source: Form 10-K revenue disaggregation note (eggs vs. butter) [5] [6] [7] [8]. Click any linked figure to open the filing page with the row highlighted.

Income Statement

Source: Consolidated Statements of Income / Operations [1] [2] [3] [4]. Click any linked figure to open the filing page with the row highlighted.

Columns marked E are consensus analyst estimates shown alongside reported results for direct comparison; they are not company guidance.

Estimate source: Yahoo Finance analyst consensus, as of 2026-07-11. Estimate figures link to the consensus source, not to filing pages.

Balance Sheet

Source: Consolidated Balance Sheets [9] [10] [11] [12]. Click any linked figure to open the filing page with the row highlighted.

Cash Flow

Source: Consolidated Statements of Cash Flows [13] [14] [15] [16]. Click any linked figure to open the filing page with the row highlighted.

Long-Term Record

Fiscal year	Total revenue	Income from operations	Net income attributable to Vital Farms, Inc.	Diluted earnings per share	Net cash from operating activities	Purchases of property, plant and equipment
FY2018	106,713	6,767	5,797	0.16	11,424	(1,940)
FY2019	140,733	3,350	2,385	0.07	(5,352)	(4,799)
FY2020	214,280	12,228	8,800	0.27	11,512	(10,300)
FY2021	260,901	52	2,429	0.06	17,682	(16,711)
FY2022	362,050	2,104	1,251	0.03	(8,098)	(10,468)
FY2023	471,857	33,254	25,566	0.59	50,906	(11,538)
FY2024	606,307	63,552	53,388	1.18	64,824	(28,646)
FY2025	759,444	88,373	66,282	1.44	33,715	(81,950)

Source: consolidated statements across filings; older years from the standardized feed [14] [1] [16] [2]. Click any linked figure to open the filing page with the row highlighted.

Analyst Consensus

Estimate source: Yahoo Finance analyst consensus, as of 2026-07-11. Estimate figures link to the consensus source, not to filing pages.

Traceability

278 of 288 figures on this page (97%) link to the filing page where they are printed — click a linked figure to open the source PDF at that page with the row highlighted. Unlinked figures come from standardized data feeds or pre-filing years.

• All figures are in thousands of US dollars as printed in the filings (per-share and share-count rows excepted), matching each 10-K's '(Amounts in thousands, except share and per share data)' basis.

• Vital Farms reports on a 52/53-week fiscal year ending the last Sunday of December (e.g., FY2025 ended December 28, 2025).

• Main statement columns FY2021-FY2025 are each sourced from that year's own Form 10-K (income, balance sheet, revenue breakdown). Cash-flow columns FY2021-FY2023 are sourced from the FY2023 10-K, which prints all three years on the current/restated basis (avoiding the FY2021 10-K's superseded operating-cash-flow classification); FY2024 and FY2025 cash-flow columns are from their own 10-Ks.

• Revenue breakdown uses the company's reported disaggregation of net revenue into eggs and egg-related products vs. butter and butter-related products.

• Long-term record FY2018 figures are from the standardized SEC XBRL data feed and are shown without page links; FY2019-FY2020 are comparative columns of the FY2021 10-K. Operating-cash-flow and capex long-term cells for FY2018-FY2020 are left unlinked because the pre-FY2021 cash-flow statements were later reclassified.

• Quarterly cash-flow single quarters are derived from the printed year-to-date statements (10-Qs print cash flow year-to-date only); see the quarterly cash-flow note. Q4 FY25 income and balance-sheet figures are cited to the Q4/FY2025 earnings 8-K (Exhibit 99.1), which prints the 13-week quarter directly.

• 5 figure(s) differed between the data feed and the filing; the filing value is shown (see the run's metrics/metrics_tab.json for the audit trail).

---

Pasture-Raised at Scale

Vital Farms sells premium pasture-raised eggs and butter sourced from a contracted network of more than 600 small farms, and has grown net revenue from $141 million in 2019 to $759 million in 2025 while turning a near-zero operating margin into 11.6%. The stock tells a different story: after peaking above $52 in August 2025 it trades near $13, roughly 75% lower, as a heavy capacity-building cycle pushes 2026 toward reported losses. This chapter establishes what the business is, how it earns, and the question the rest of the report answers.

What the company is

Vital Farms is a branded consumer-staples company built around a single differentiated claim: eggs and butter from animals raised on pasture, sourced through a "distributed supply chain of small farms" rather than industrial cages or barns [1]. It was founded in 2007 on a 27-acre plot in Austin, Texas, sold its first eggs at farmers markets, and was picked up by Whole Foods within a year [2]. It is a Delaware public benefit corporation and a Certified B Corporation — a legal structure that binds management to stakeholders beyond shareholders, and a governance fact worth carrying forward for a value investor [3].

The model is asset-light at the hen and asset-heavy at the plant. Vital Farms does not own most of the farms; it contracts with a network of more than 600 family farms that raise the birds, and concentrates its own capital in processing — a shell-egg washing and grading facility called Egg Central Station in Springfield, Missouri [4]. In 2024 it began adding company-owned "accelerator farms" to test practices at scale, and it began placing birds on them in 2025 [5].

By its own measure, the brand leads its niche: Vital Farms reports it is the #1 U.S. pasture-raised egg brand, #1 in the natural channel, and #2 U.S. egg brand overall by retail dollar sales [6]. It competes with commodity egg producers such as Cal-Maine Foods, international brands such as Ornua's Kerrygold in butter, and — increasingly — private-label pasture-raised eggs [7].

How the economics have moved

The growth record is the clearest fact in the file. Revenue compounded at roughly 32% a year over six years, and gross profit rose in step.

Source: FY2025 Annual Report (Form 10-K), five-year performance graphic and Consolidated Statements of Operations [8].

Profitability is a more recent development. Operating margin was effectively zero through 2021–2022 — the company earned $2 million of operating income on $362 million of revenue in 2022 — before recovering to 11.6% in 2025. The swing reflects operating leverage over a plant-heavy cost base and firmer pricing, not a change in what the company sells.

Source: derived from reported financials, FY2019–FY2025 10-Ks; income from operations per FY2025 Annual Report (Form 10-K), Consolidated Statements of Income [9].

Source: FY2025 Annual Report (Form 10-K), Consolidated Statements of Income [10].

One structural point sits underneath the growth. The company's own history graphic shows store count essentially flat — about 24,000 retail locations across 2023, 2024 and 2025 — even as revenue rose from $472 million to $759 million over the same span [11]. Recent growth has come from selling more through the same shelves — deeper household penetration, more units per store, higher price — rather than from new doors. Whether that velocity persists is a question a later chapter takes up.

The stock: a round trip

For a reader meeting the name now, the share price is the first puzzle. Vital Farms came public in July 2020 near $35, fell to roughly $8 in 2022, then ran to an intraday high above $52 in August 2025 before collapsing back toward $13 by mid-2026 — a full round trip that left the stock about 75% below its 2025 peak even though revenue and profit kept rising.

Source: company share price history, as reported (2026 shown through July 10, 2026).

The gap between a business tripling in size and a stock cut to a quarter of its peak is the tension the report exists to resolve. At about $13, the shares carry a market value near $596 million against $66 million of 2025 net income — roughly 9 times trailing earnings — for a company that grew revenue 25% last year.

Source: share price and shares outstanding, as reported; trailing diluted EPS of $1.44 from FY2025 Annual Report (Form 10-K), Consolidated Statements of Income [12].

Why the market turned: the investment cycle

The re-rating coincides with a deliberate shift into a heavy spending phase. Capital expenditure jumped to about $82 million in 2025 as the company built out capacity, and free cash flow — reliably positive in 2023 and 2024 — swung to roughly negative $48 million. Vital Farms broke ground in 2025 on Vital Crossroads, a second washing-and-packing facility in Seymour, Indiana, that it expects to be fully operational in 2027 [13].

Source: derived from reported financials, FY2020–FY2025 Consolidated Statements of Cash Flows [14].

Management has framed this as a phase, not a new normal. In December 2025 it set a target of $2 billion in net revenue by 2030 with 15% to 17% adjusted EBITDA margins and gross margins above 35%, and guided initial 2026 net revenue to $930–950 million — continued growth of roughly a quarter [15] — while describing 2026 as a transition "from capacity building to market expansion" [16]. The near-term cost of that transition is real: the company itself warns that rising operating and capital expenses may prevent it from maintaining or increasing profitability, and consensus now expects Vital Farms to report losses through 2026 even as revenue climbs [17]. That is the shape of a "worse before better" year rather than a broken business — but the burden of proof is on execution.

The balance sheet and the governance flag

For a reader who screens out anything that could go bankrupt, the balance sheet is reassuring. Vital Farms funds this cycle from cash and a $60 million revolving credit facility that carries no drawn term debt, secured on substantially all its assets and undrawn as a backstop [18]. With shareholders' equity of $351 million and no meaningful leverage, near-term solvency is not the risk; execution and returns on the new plants are.

Governance carries a fresh complication. Founder Matthew O'Hayer — the largest holder, whose stake has fallen from about 27% at the IPO toward 16% — resigned as Executive Chairperson, board member, and employee effective February 24, 2026, and the board handed the combined Executive Chairperson, President and CEO roles to Russell Diez-Canseco [19]. A founder's departure and a combined chair/CEO are exactly the governance details this reader weighs, and they warrant a chapter of their own.

The question this report answers

Vital Farms is a genuine category leader trading like a broken one, in the middle of a self-inflicted investment year. The question the rest of this report exists to answer is whether Vital Farms can convert its lead in pasture-raised eggs — a brand-and-farmer-network model that has compounded revenue near 30% a year and finally earned double-digit operating margins — into durable, consistent free cash flow on the path to its $2 billion-by-2030 ambition, or whether a premium egg brand remains hostage to commodity feed and egg-price swings, avian-influenza supply shocks, and the private-label competition now entering the category it created. Each chapter that follows tests one part of that question against the filings.

---

Cash Conversion

Vital Farms grew net revenue from roughly $107M to $759M over eight fiscal years and earned $166M of cumulative net income — yet turned only about $10M of that into cumulative free cash flow, roughly six cents on the dollar. The rest went to capital spending and, in 2025, a large working-capital build. Free cash flow has been thin, lumpy, and is now in its deepest trough as the company funds its largest-ever capacity build into a commodity-egg price shock. The balance sheet can fund it; the durability of the cash generation on the other side is the open question.

The record: profit has rarely become free cash

Source: derived from reported financials; FY2025 Annual Report (Form 10-K), Consolidated Statements of Cash Flows [1].

The single most useful lens on this business is how reliably reported earnings convert to cash a shareholder could take out. Over eight years, they largely have not. Cumulative operating cash flow of $177M funded cumulative capex of $166M, leaving about $10M of cumulative free cash flow against $166M of cumulative net income [2]. Free cash flow was negative in three of the eight years and never exceeded $40M in any of them.

Source: derived from reported financials, FY2018–FY2025 10-Ks; FY2023–FY2025 figures per FY2025 Annual Report, Consolidated Statements of Cash Flows [3].

Two things are true at once here. The reinvestment has worked: the capital that suppressed free cash flow also grew the business more than sevenfold and lifted operating margin from near zero to double digits. And even in the two best years — FY2023 and FY2024 — free cash flow of $39M and $36M represented free-cash-flow margins of only 8% and 6%. This is not yet a high-cash-conversion business; it is a fast-growing one that has plowed nearly all its operating cash back into capacity.

FY2025: why record profit produced negative cash

The FY2025 swing was large and has two distinct causes. Free cash flow fell $84M year-on-year, from positive $36M to negative $48M. Roughly two-thirds of that is deliberate growth capital; the remainder is a working-capital build that deserves closer attention.

Source: derived from FY2025 Annual Report, Consolidated Statements of Cash Flows [4].

Capex tripled to $82.0M as the company broke ground on Vital Crossroads — a second automated egg washing and packing plant in Seymour, Indiana — and built a second processing line at Egg Central Station simultaneously rather than in phases [5]. Against depreciation of $13.8M and a pre-build capex run-rate near $11M–$15M, roughly $67M of the $82M is genuine growth investment, not maintenance [6]. That portion is discretionary and, as 2026 has since shown, reversible.

The second cause is less discretionary. Operating cash flow itself fell from $64.8M to $33.7M even as net income rose, because inventory swung from an $8.9M source of cash in 2024 to a $47.8M use in 2025, and lease payments consumed a further $34.7M [7]. Inventory on the balance sheet nearly tripled, from $23.7M to $66.5M [8].

Source: FY2025 Annual Report (Form 10-K), Note 8 — Inventories [9].

The egg inventory line quadrupled, and the reserve for inventory obsolescence jumped from $0.2M to $4.9M in a single year [10]. Building inventory while writing more of it down was an early signal of a structural feature that became the central story of 2026: because Vital Farms contracts to buy eggs from its farmer network regardless of retail demand, a demand slowdown does not reduce supply — it becomes surplus eggs the company must move at a loss.

The 2026 reset: the commodity link, made visible

Through 2025, management framed negative free cash flow as a choice. On the second-quarter 2025 call, the CFO said the company expected "free cash flow to turn negative this year after two very strong positive years," having pulled Seymour capex forward, and reiterated that every capex dollar in Seymour should generate more than $5 of annual revenue capacity [11]. In February 2026, the company guided FY2026 capex up again to $140M–$150M and told investors to expect "a meaningful pivot to strong, sustainable free cash flow generation in 2027 and beyond, once the heavy spending" was complete, alongside a reaffirmed target of $2 billion of net revenue by 2030 and a new $100M buyback authorization [12].

Ten weeks later, that plan changed materially. On the May 2026 first-quarter call, management reported a first-quarter net loss of $1.5M against a $16.9M profit a year earlier, with adjusted EBITDA margin collapsing from 17% to under 3% [13]. The cause was a commodity-price collapse: as mainstream egg prices fell to multi-year lows — breaker eggs traded as low as $0.10 per dozen — Vital Farms' price gap to competitors widened past what its brand could hold, new-household trial dropped, and the company found itself with surplus eggs it had contracted to buy [14]. Management said it had "found the limits of what our brand could sustain" [15].

The cash response was a sharp reversal of the prior six months of guidance.

Source: Q4 FY2025 Earnings Call [16]; Q1 FY2026 Earnings Call [17].

Between February and May, the FY2026 revenue guide fell from $900M–$920M to $775M–$800M, the adjusted EBITDA guide fell from $105M–$115M to $0–$10M, and the capex guide was cut from $140M–$150M to $70M–$75M [18]. To preserve cash, management decided to exit the butter business entirely (freeing an estimated $25M and cutting about $14M of 2026 revenue), eliminated roughly 10% of non-plant headcount, and slowed Seymour construction while pausing accelerator-farm build-out [19]. The company still expects "negative free cash flow this year" and now anticipates funding it partly through its revolver [20].

Can it fund the trough

For a value investor the first cash question is solvency, and here the answer is reassuring, if less comfortable than a year ago. Vital Farms carries no term debt. It holds a $60.0M five-year revolving facility with JPMorgan, undrawn at year-end 2025, with financial covenants of a net leverage ratio no greater than 3.25x and a fixed-charge coverage ratio no less than 1.35x [21].

The cushion is shrinking quickly, though. Cash, equivalents and marketable securities fell from $113.4M at year-end 2025 to $51.4M by the end of the first quarter of 2026 — a $62M draw in one quarter, reflecting the inventory build, supply-management costs, continued capex, and $20M of buybacks [22]. With capex now cut to $70M–$75M, the butter exit adding cash, and $60M of undrawn revolver capacity, the near-term funding gap looks manageable, and there is no near-term maturity to refinance. The binding constraint to watch is not liquidity itself but the fixed-charge coverage covenant if adjusted EBITDA sits near the bottom of the $0–$10M guide and the company draws the revolver — a threshold worth checking each quarter. Solvency is not the risk today; the risk is that a further leg down in category pricing, which management explicitly flagged as possible, deepens and lengthens the cash draw.

One capital-allocation choice sits awkwardly against that draw: the board authorized a $100M, two-year buyback in February and had spent $20M of it by March, with $80M remaining, while free cash flow was negative and cash was falling [23]. Repurchasing a stock down heavily from its peak can be accretive if the recovery arrives; funding it from a shrinking cash pile during the company's deepest cash trough is a bet that the trough is temporary. On the accounting side, the one governance-adjacent flag on cash and earnings quality — a material weakness in revenue and accounts-receivable controls identified for FY2024 — was remediated as of December 28, 2025, with no restatement [24].

The pivot the case depends on

The setup is the kind a patient investor is built for: a category leader in its deepest cash trough, spending heavily now against a promise of harvest later. Management's math is internally coherent. If Seymour delivers more than $5 of revenue capacity per capex dollar, if the $2 billion 2030 revenue target is met at a 15%–17% adjusted-EBITDA margin, and if capex normalizes toward maintenance once the plants are built, steady-state free cash flow could plausibly reach $150M–$180M a year — a genuine owner-cash business [25]. The category tailwind is real: outdoor-access eggs grew from 8% of category volume in 2023 to 15% by early 2026, even with commodity eggs at their cheapest in years [26].

The case against giving that promise the benefit of the doubt rests on three facts, and they deserve equal weight. First, the guidance has moved a long way, fast: the FY2026 adjusted-EBITDA outlook fell from roughly $110M to about $5M in ten weeks, which is a wide miss on management's own near-term forecasting. Second, the surplus-egg episode is not a one-off macro event but a visible expression of the model itself — fixed egg supply meeting variable demand — which caps how much of a commodity-cost swing the brand premium can absorb. Third, "strong, sustainable free cash flow" has been asserted, not demonstrated: across eight public years the company has generated about $10M of it in total, and the promised 2027 pivot has already slipped once as capex was cut to defend the balance sheet rather than to build the capacity the growth target requires.

My read is that Vital Farms is a credible franchise that has not yet proven it can convert profit into durable owner cash, and that 2026 is the year the model's commodity exposure and its cash-conversion question are being tested in the open rather than in theory. The evidence for the bull case is the category's growth and the clean, debt-free balance sheet; the evidence against is a low structural free-cash-flow margin, rising working-capital intensity, and a forecasting record that has just been marked down hard. What would change the read in either direction is concrete and checkable: adjusted EBITDA re-crossing double-digit margins and inventory normalizing back toward one turn of its 2024 level would support the harvest thesis; a second downward capex-or-EBITDA revision, or a revolver draw that puts the fixed-charge covenant in play, would confirm the skeptic's.

---

Ownership and Control

Vital Farms' cap table is unusual for a founder-led consumer company. Founder Matthew O'Hayer has cut his stake from 27.4% at the IPO to 16.3% and, in February 2026, left the board entirely; current officers and directors together own under 4%, and two index funds hold roughly 19% [1]. Governance hygiene is largely sound, but three features bear on the reinvestment cycle: a combined chair and CEO, a construction contract with the CEO's father, and a public-benefit charter that legally subordinates share-price maximization.

The owner's table

As of April 2026, Vital Farms had 42.8 million shares outstanding, and the register concentrates in a small set of names [2]. The founder remains the single largest holder at 16.3%. The two big passive managers, BlackRock and Vanguard, together hold about 19%. Everyone actually running the company — all 15 executive officers and directors as a group — owns 3.9%, and the chair-and-CEO himself owns 1.9%.

Source: 2026 Proxy Statement, Security Ownership table (42,848,454 shares outstanding as of April 23, 2026) [3].

Source: 2026 Proxy Statement, Security Ownership of Certain Beneficial Owners and Management [4].

The register has no dual-class structure and no super-voting shares: economic ownership and voting power are the same thing. That matters for a minority holder — control here follows the cash-on-the-table register, not a founder's protected vote. It also means the passive index funds, not any insider, are now the swing block on any shareholder vote.

The founder steps back

O'Hayer's ownership has fallen in a steady line, not a cliff. Successive Schedule 13G filings show the stake moving from 27.4% (February 2021) through 23.4% (February 2024) to 16.1% (November 2025), before the proxy recorded 16.3% in April 2026 [5]. That is roughly 11 percentage points of the company distributed over five years — a deliberate, disclosed wind-down rather than a single exit.

Source: SEC Schedule 13G / 13G-A filings, 2021–2026; latest point confirmed in the 2026 Proxy Statement [6].

The step change is at the board, not in the stake. O'Hayer resigned as Executive Chairperson and left the board in February 2026, and in March 2026 signed a resignation agreement under which he serves only as a non-employee advisor, drawing no compensation in fiscal 2025 [7]. The founder who built the farmer network is now a large but passive shareholder — one who has been a consistent seller — with no formal control of the company he founded.

Control concentrates as the founder leaves

O'Hayer's departure did not disperse authority; it consolidated it. Russell Diez-Canseco now holds all three top roles — President, Chief Executive Officer, and Executive Chairperson — and is the only one of the eight directors the board does not classify as independent [8]. The remaining seven directors are independent, and Denny Marie Post serves as Lead Independent Director, the structural counterweight to a combined chair and CEO [9].

The surrounding hygiene is better than the concentrated top job might suggest. The board runs a clawback policy on incentive pay, prohibits hedging and all but tightly-controlled pledging of shares, and raised its stock-ownership guidelines in 2025 to five times base salary for the CEO — with every officer and director reported in compliance [10]. Management pay is modest for the size of the business: the CEO's fiscal-2025 total compensation was $3.6 million, of which roughly $2.1 million was equity, for a CEO-to-median-employee pay ratio of 44:1 [11] [12].

Two features cut the other way. The board is classified into three staggered classes, each serving a three-year term, so only part of the board stands for election in any year — an entrenchment feature that slows any outside push for change, and one the board has explicitly chosen to keep [13]. And the concentration of chair and CEO arrives precisely as the company enters its most capital-intensive stretch — the multi-year plant build that governs whether the free-cash-flow question resolves (Cash Conversion). Independent oversight of that spend now rests on a lead director and committee structure rather than a separate chair.

The related-party build

The sharpest company-specific flag sits inside the capital program itself. Vital Farms uses Sandpebble Builders Preconstruction for project-management services on its egg-processing facilities, including Vital Crossroads, the second washing-and-packing plant in Seymour, Indiana. Victor Canseco, Sandpebble's owner and principal, is the father of CEO Russell Diez-Canseco, and the company paid Sandpebble approximately $2.46 million in fiscal 2025 [14].

The amount is small against the roughly $82 million of fiscal-2025 capex, and the payment is disclosed and routed through the audit committee's related-person-transaction policy, which requires arm's-length review of any deal above $120,000 [15]. What makes it worth a professional investor's attention is not the size but the location: the CEO's family is a paid vendor on the very growth-capex build that the investment case turns on, and that vendor relationship persists into the larger Vital Crossroads spend still ahead. The read here is a watch item, not an indictment — the disclosure is clean and the sum immaterial — but a related-party vendor embedded in the swing capital project is the kind of arrangement whose scale is worth tracking as Vital Crossroads ramps.

Sellers on the way up, buyers at the bottom

Insider trading over the last twelve months splits cleanly by direction and by timing. On the way up, the selling was concentrated in the two most senior insiders: O'Hayer disposed of 95,000 shares for about $2.7 million and Diez-Canseco sold 16,734 shares for about $0.6 million, both through pre-set 10b5-1 plans.

The buying tells the more interesting story. After the stock's roughly 75% drawdown and the May 2026 guidance cut, a broad group of directors and officers bought on the open market — thirteen purchases totaling about $0.6 million, with eleven of them clustered in a single week of mid-May at prices near $8 to $10.

Source: SEC Form 4 filings, open-market purchases March–May 2026 (aggregated); larger 10b5-1 sales by O'Hayer and Diez-Canseco over the same window are drawn from the same filings.

The buying is a genuine signal, but it deserves a fair caveat. Directors and officers face a five-year runway to meet the raised ownership guidelines, so some of these purchases help satisfy that requirement rather than express pure conviction [16]. Even so, the concentration of eleven insiders buying in one week, at multi-year lows, after the worst guidance cut in the company's public life, is the first cluster of open-market insider buying in the record — a datapoint that cuts against the bear case on management's own read of value.

The public-benefit lens

One structural feature of Vital Farms is not a discretionary governance choice but a charter obligation. As a Delaware public benefit corporation and Certified B Corp, the board has a legal duty to balance three things: the pecuniary interest of stockholders, the interests of those materially affected by the company's conduct, and the specific public benefits named in its certificate of incorporation [17].

The company's own filings state the consequence plainly: in balancing these interests, the board "may take actions that do not maximize stockholder value" [18]. The structure also creates a litigation channel that ordinary corporations lack: holders of as little as 2% of shares (or $2 million of stock) can bring a derivative claim alleging the board failed to balance those interests [19]. For most of the company's history this has been an abstraction, aligned with the brand that commands the price premium. It becomes a live question only if the stakeholder mission and shareholder returns ever pull hard in opposite directions — a tension a minority holder accepts as a condition of owning the shares.

Where this leaves the reader

The ownership picture is a balance of alignment and concern, not a verdict either way. On the alignment side: no dual-class control, an independent board majority with a lead independent director, disciplined pay, hedging and pledging restrictions, and a cluster of insider buying at the lows. On the concern side: a founder who has sold steadily and left, a chair-and-CEO role concentrated in one person just as the capital cycle peaks, a classified board that resists outside pressure, a related-party vendor inside the growth-capex program, and a charter that legally permits the board to weigh other interests above the share price. None of these is disqualifying on its own; together they describe a company where a minority investor is trusting an independent board and a lead director — rather than a large aligned insider block — to steward the reinvestment that the thesis depends on.

---

Category and Moat

Vital Farms sits in the fastest-growing corner of a large, staple category, and it is gaining share there: pasture-raised egg volume grew about 27% a year from 2020 to 2025 while conventional eggs shrank, and household penetration climbed from roughly 2% at the 2020 IPO to about 10.5% [1]. The demand is structural. The moat protecting it is a brand and a farmer network, not a cost or a patent — and it is now being tested by private label and by far larger, better-capitalized producers.

The category is a structural shift, not a fad

The case for durable growth starts with where the volume is going. Across 2020 to 2025, pasture-raised was the only egg segment growing fast — about 27% a year by volume — while conventional eggs, still the bulk of the market, declined about 6% a year and the mid-tier cage-free and free-range segments grew around 12% [2]. This is consumers trading up within an everyday purchase, not a novelty spike.

Source: 2025 Investor Day presentation, Circana segment volume data [3].

The same pattern shows up in dollars and in penetration of the shelf. Eggs from hens with outdoor access rose from 5.7% of U.S. shell-egg volume in 2020 to 13.0% in 2025 [4], and the pasture-raised retail egg market reached roughly $1.3 billion in 2025, compounding about 37.5% a year since 2021 [5]. That $1.3 billion is still only a sliver of the roughly $15.4 billion U.S. shell-egg market [6] — the runway argument in one number.

Source: FY2025 Annual Report, Industry Overview (Circana retail-sales data); Vital Farms net revenue as reported [7].

One caution belongs on the shell-egg number: the reported 21.3% category CAGR since 2021 is inflated by avian-influenza-driven egg-price spikes, not by unit demand. The U.S. egg-laying flock was still about 301 million birds in September 2025, below the roughly 341 million of January 2020 [8]. The durable signal is the volume mix shift toward outdoor access, not the headline dollar growth.

The runway: penetration is low, and buyers stay

Vital Farms reaches about 10.5% of U.S. households against category penetration near 97% [9] — nearly 16 million homes, served through roughly 24,000 stores [10]. Penetration has more than doubled since the 2020 IPO.

Source: company filings and earnings calls — 2020 IPO prospectus and FY2021–FY2022 10-Ks (SPINS); 2023–2024 per the Q4 FY2024 call; 2025 per the FY2025 10-K (Circana) [11]; [12].

Two things temper the runway read. First, the climb flattened: penetration was 10.7% in 2024 and about 10.5% in 2025 (the measurement source also shifted from SPINS to Circana), so the 25% revenue gain in 2025 came from existing buyers purchasing more, not from a widening base [13]. Second, the offsetting strength is real: when Vital Farms adds a household it tends to keep it, buy rate rose 12% to $36.06 in 2024, and brand awareness climbed 8 points to 34% in 2025 [14]. The growth model has shifted from "more doors" (Pasture-Raised at Scale) to "more homes and deeper baskets," and the deeper-basket half is doing the heavier lifting.

Vital is winning share — the moat is a brand and a network

Within this category Vital Farms is the leader and still gaining. It is the #1 U.S. pasture-raised brand, #1 in the natural channel, and #2 U.S. egg brand overall by retail dollar sales [15], and it was the top volume-share gainer among premium shell-egg brands in 2025, adding 25 basis points of share (35 basis points in early 2026) [16]. As of December 2025 it was the number-one or number-two branded egg at nine of its ten largest customers [17].

The moat has three parts, and all three are brand- or relationship-based rather than structural. It is a trusted consumer brand built on transparency and animal welfare; a contracted network of more than 600 family farms operating to the Certified Humane pasture-raised standard of 108 square feet of outdoor space per hen, hard to assemble at national scale; and a set of retailer relationships in which Vital's eggs earn premium shelf economics. None of these is a cost advantage or a patent. That is the central fact about the moat: it is durable only as long as the brand keeps commanding a premium and the farmer network stays ahead of demand.

The two-sided test: private label and larger rivals

The premium is being probed from two directions, and this is where a cautious reader should linger rather than accept the leader's framing.

Private label is entering the category Vital created. Private-label pasture-raised eggs grew from about 0.1% of U.S. shell-egg volume in 2020 to 1.0% in the first half of 2025 — while Vital's own share rose from 1.0% to 3.2% over the same span [18].

Source: August 2025 corporate presentation, Circana volume-share data (2025 is first-half) [19].

Management's read is that private label is expanding the category rather than taking from brands — pulling commodity-egg buyers up into outdoor access, not converting Vital's customers [20], and the CEO has called private label's ability to trade its own shoppers up "quite strong" and a validation of the category [21]. The skeptical counter is on the same chart: private-label pasture-raised volume share grew roughly ten-fold over five years against Vital's roughly three-fold, so private label is the faster-growing entrant even if it is smaller, and it now equals about a third of Vital's shell-egg share, up from a tenth in 2020. A related tell sits in the filings themselves — the 2021 10-K quantified Vital's grip as an 88% share of the U.S. pasture-raised retail egg market [22]; the FY2025 10-K repeats the "#1 pasture-raised" claim but no longer discloses a category share [23]. The most likely reason a company drops a share statistic is that the number moved the wrong way.

Larger, better-capitalized producers are moving into premium eggs. Vital's own risk factors describe an industry "dominated by multinational corporations with substantially greater resources," warn that conventional food companies may acquire competitors or launch their own premium products, and note increasing consolidation among specialty-egg companies [24]. This is not hypothetical. Cal-Maine Foods — the largest U.S. egg producer — already sells pasture-raised eggs under its Farmhouse Eggs and Egg-Land's Best brands, markets private-label specialty eggs to retailers, and is expanding specialty capacity through acquisitions [25]. A commodity producer with national scale, low-cost hens, and an M&A budget is a different kind of competitor than the small branded rivals Vital outgrew on the way up.

The premium is discretionary, and 2026 showed what that costs. When commodity egg prices collapsed in early 2026, the gap between a carton of Vital Farms and a carton of store-brand eggs widened, trial slowed, and some shoppers traded down — the mechanism examined in Cash Conversion. That episode is the clearest evidence that the moat is cyclically exposed: the brand commands a premium in normal times, but the size of that premium — and therefore trial and mix — moves with a commodity price Vital does not control. A moat that holds in good conditions and narrows in a commodity glut is real, but it is not the fortress a leader's market-share language implies.

What the evidence supports, and what would change it

The weight of the evidence is that the category is a durable, structurally-growing shift with a long runway — pasture-raised is genuinely the fastest-growing segment, penetration is low against a near-universal category, and Vital is the clear leader still gaining share. The strongest fact against a clean bull read is that the protection around that lead is a brand premium, not a cost or supply advantage, and that premium is being pressured on price by private label, on capital and scale by much larger entrants, and on trial by the commodity cycle. The read that fits both sides: a strong position in a good category, defended by a moat that is real but narrower and more cyclical than the "#1" framing suggests.

Three things would move the assessment. Penetration resuming its climb above roughly 10.5% would confirm the runway is still opening rather than maturing; the reverse would say the accessible base is closer to full. Vital holding or extending its share as private-label pasture-raised scales — rather than the two converging — would show the brand premium survives contact with a cheaper shelf equivalent. And pricing power holding through the next commodity swing, with the premium and trial stable rather than compressing, would tell whether the moat is durable or merely fair-weather.

---

Normalized Value

At $12.95, Vital Farms trades at about 9x its record fiscal-2025 earnings and 4.6x that year's adjusted EBITDA — multiples that look cheap only because fiscal 2025 was the peak of the cycle. Management guides 2026 EBITDA to near zero and a recovery to double-digit margins in 2027. The valuation is most sensitive to the normalized operating margin; on the same ~$800 million of revenue, plausible margin assumptions produce earnings anywhere from $0.18 to $1.54 a share.

What you pay today

Fiscal 2025 was a record year: net revenue of $759.4 million, net income of $66.3 million, diluted EPS of $1.44, and adjusted EBITDA of $114.0 million — a 15.0% margin [1]. Against a $12.95 share price and about 44.6 million shares, the equity is worth roughly $577 million. Net of $51 million of cash and investment securities, enterprise value is about $526 million.

Sources: FY2025 net income, EPS and adjusted EBITDA, Q4/FY2025 earnings release [2]; cash, securities and no-debt balance sheet [3]; price and share count per market data.

The trailing figures are the source of the "cheap" impression — 9x earnings and under 5x EBITDA are low marks for a brand growing revenue at a mid-20s percentage rate. The problem is what sits inside the denominator. Fiscal 2025 earned a 15.0% adjusted EBITDA margin, the highest in the company's history and roughly triple the level of only three years earlier. For fiscal 2026, management guides adjusted EBITDA to $0–10 million on revenue of $775–800 million — a margin near 1% — as it spends an estimated $32 million to manage an oversupply of eggs and exits the butter business [4]. On that guided number, the forward EV/EBITDA multiple is not low; it is undefined. The trailing multiple prices earnings power the company itself says will disappear for a year.

The de-rating that carried the stock here reflects exactly that. At the August 2025 peak near $52, the equity was worth about $2.3 billion — roughly 20x the $114 million of adjusted EBITDA fiscal 2025 went on to report. The same EBITDA base now carries an enterprise value of about $526 million, or 4.6x. The multiple has done most of the work; the earnings base has not yet moved.

Source: derived from FY2025 adjusted EBITDA of $114.0 million [5] and peak/current market values per price data.

The margin is the valuation

Because revenue is comparatively stable — the 2026 guide of $775–800 million sits close to 2025's $759 million — the earnings the reader is buying depend almost entirely on where the operating margin settles once the 2026 supply-management costs roll off. The table below holds normalized revenue at roughly $820 million and flexes only the through-cycle adjusted EBITDA margin. Net income is built down from EBITDA using depreciation of about $18 million (rising as the new plants come on line), stock-based compensation near $14 million, modest net interest income, and a 26% tax rate.

Source: derived from reported fiscal-2025 financials and the fiscal-2026 revenue guide; normalized revenue held at ~$820M [6][7].

The spread is the point. The same revenue produces $0.18 or $1.54 of earnings — an eight-fold range — depending only on the normalized margin. At a 15% margin the stock is genuinely cheap at roughly 8x earnings; at a 5% margin it is a value trap at more than 70x. The valuation is most sensitive to this single variable, and the depreciation from Vital's newly built capacity amplifies the downside: at a low EBITDA margin, fixed plant costs consume most of what is left, so net income falls faster than the margin does.

Management's own roadmap sits between the top two rows. On the Q1 2026 call it guided gross margin back to 30% by late in the fourth quarter and "underlying adjusted EBITDA margin to get back to double-digits in 2027," describing a "clear path back to the earnings profile implied by our long-term model" [8]. The 2030 framework is more ambitious still: $2 billion of revenue at a 15–17% adjusted EBITDA margin [9]. Buying the "Recovery" row means underwriting that the double-digit target is reached and held.

What the price implies

Read the other way, $12.95 is not pricing the recovery — nor a permanent impairment. To trade at a normal packaged-foods multiple of roughly 10x EV/EBITDA, today's $526 million enterprise value implies normalized adjusted EBITDA near $53 million, or about 6–7% of $820 million of revenue. That is well above the ~1% guided for 2026 and well below the 15% earned in 2025. In plain terms, the market is paying for margins that heal part of the way out of the 2026 trough and then stall in the mid-single digits.

Consensus lines up with that reading. The sell-side mean price target is $12.00 — below the current price — with a $10–16 range. Analysts have cut fiscal-2027 EPS from $1.39 ninety days ago to $0.44 now, and the revisions are still moving down. A $0.44 estimate implies a low-single-digit net margin, closer to the "Structural reset" row than to management's double-digit guidance.

Source: consensus estimates (9–10 analysts), as of July 2026.

So the arithmetic gap that defines the opportunity is narrow but real: the price and the Street both embed a partial, mid-single-digit recovery; management underwrites a return to double digits; and the reader's return depends on which of those margins actually arrives. The upside case is not that the multiple is wrong — at 4.6x trailing EBITDA it is demonstrably low — but that the earnings base recovers faster than consensus now expects.

The case against normalization

The through-line of this report asks whether a premium egg brand can turn its lead into durable cash, or whether it stays hostage to commodity swings and private-label entry. A valuation built on "2026 is a trough" deserves the opposite hypothesis given a fair hearing: that 2026 is not a discrete shock but a structural reset of the margin, in which case the mid-single-digit outcome is the normalized one and the stock is fairly valued to expensive.

The bear mechanism is specific. The 2026 damage came from a collapse in commodity egg prices — breaker eggs near $0.10 a dozen — which widened the price gap between Vital's outdoor-access eggs and the conventional shelf, cut trial, and forced the company to dump excess supply into no-revenue channels. If cheap commodity eggs persist and private-label pasture-raised keeps undercutting — its share of the pasture-raised segment rose roughly ten-fold while Vital's roughly tripled, as detailed in Category and Moat — then the premium's pricing power is structurally capped, and the "double-digit margin in 2027" does not arrive on schedule. The newly built capacity works against the reset case too: depreciation and fixed plant cost are now permanent, so the asset-light margin profile of Vital's earlier years is unlikely to return in full.

Three facts keep the reset case alive rather than academic. Consensus itself does not believe the recovery — a $0.44 fiscal-2027 estimate and a $12.00 mean target embed only a partial heal. The estimate trend is still down, not stabilizing. And management's recovery is explicitly conditioned on prices holding: the CFO warned that if outdoor-access retail prices "erode further," Vital would spend more to close price gaps, cutting revenue and profit further [10]. The recovery is a forecast resting on an assumption the company does not control.

The bull's answer is equally concrete, and belongs in the same frame: the pasture-raised category is still growing volume at a high-20s percentage rate off roughly 10% household penetration (Category and Moat); the $32 million of 2026 supply-management cost is identified and one-time; management has real cost levers in the butter exit, a headcount reduction, and capex cut from $140–150 million to $70–75 million [11]; and the debt-free balance sheet lets the company wait out the trough without financing pressure (Cash Conversion). The evidence does not settle the question. What would settle it is measurable within four to six quarters: whether gross margin returns toward 30% by late 2026 and whether the 2027 adjusted EBITDA margin re-enters double digits.

Downside and the balance-sheet floor

The debt-free balance sheet is a genuine strength, but it should not be mistaken for a price floor near current levels. Book value is about $7.42 a share; net cash is roughly $1 a share. At $12.95 the stock trades at about 1.75x book, so the tangible-asset floor sits some 43% below the current price. The absence of debt removes solvency risk — covered in Cash Conversion — but it does not stop the multiple compressing toward book if the recovery stalls. The May 2026 low of $8.28, about 1.1x book, is a recent demonstration of how far sentiment can travel when the earnings base is in doubt.

Management's capital-allocation signal has been mixed on timing. The board authorized a $100 million, two-year buyback in February 2026, framed as buying "particularly during periods where management believes the public market price does not fully reflect intrinsic value" [12]. It then spent the first $20 million in the first quarter, repurchasing over one million shares while the stock averaged about $23.63 — nearly double today's price — leaving $80 million authorized as of late March [13]. The remaining authorization, deployable now near book value, is worth more than the tranche already spent above it.

Source: book value derived from Q1 FY2026 stockholders' equity of $330.9 million over ~44.6M shares [14]; price anchors per market data.

What would decide it

The valuation resolves on two falsifiable, near-term markers, both stated by management and checkable in the quarterly filings. First, gross margin: guided back to 30% by late in the fourth quarter of 2026 [15] against roughly 37% in 2025 and a 2026 trough — the reported gross-margin line each quarter tells you whether the price gap is closing. Second, the fiscal-2027 adjusted EBITDA margin: a return to double digits validates the "Recovery" or "Partial heal" rows and the low trailing multiple; a stall in the mid-single digits validates the reset case and makes today's price full. On the evidence available now — a low trailing multiple, a stable revenue base, a debt-free balance sheet, but a still-falling consensus and a recovery contingent on egg prices the company cannot set — the setup rewards patience only if the margin heals, and the next two to three prints will show which way it is going.

---

The Growth Engine

The $2 billion 2030 revenue target implies about 21% annual growth for five years, down from the roughly 32% Vital Farms compounded over 2019–2025 [1]. Management has narrowed how it intends to get there: more households buying shell eggs more often, on a store base flat since 2023, while every non-core product — egg bites, ghee, tub butter, and now stick butter — has been discontinued [2]. Processing capacity was built ahead of demand that softened in 2026.

The target and the pace it requires

Vital Farms grew net revenue from $141M in 2019 to $759M in 2025 [3], a compound rate near 32% a year. The 2030 framework set at the December 2025 Investor Day — $2 billion in net revenue, a gross margin above 35%, and a 15–17% adjusted EBITDA margin [4] — asks for a slower but still demanding pace: roughly 21% a year off the 2025 base, the figure the CFO calls the company's "21% long-term CAGR" [5].

Source: net revenue FY2019–FY2025 per company reported financials, with FY2025 also stated in the FY2025 Annual Report [6]; 2030 target per December 2025 Investor Day [7].

This is the second time the long-term goalpost has moved. Through 2024 the standing target was $1 billion in net revenue by 2027 at a 12–14% EBITDA margin [8]; the Investor Day both doubled the revenue ambition and lifted the margin ceiling to 15–17%. Raising a target while the business is compounding is a sign of confidence, but it also means the 2030 number is a newer, less-tested commitment than the headline suggests.

The 2026 reset makes the remaining path steeper than the 21% headline. After first-quarter velocities fell short, management cut fiscal-2026 revenue guidance to $775–800M — "at least 5% growth" — from the $900–920M set only three months earlier [9] [10]. Off an $800M 2026 base, reaching $2 billion by 2030 requires about 26% a year for the following four years — faster than the company's own long-run average and well above the pace it is guiding for this year. The plan is back-end-loaded, and 2026 spends one of its five years standing nearly still.

How growth happens now

Distribution is no longer the lever. Store count has been essentially flat at about 24,000 since 2023 [11], so revenue now grows by selling more through the same shelves: converting brand awareness into new households, and existing households into heavier buyers. The Investor Day action plan lays this out as six workstreams — brand awareness and household penetration, farmer recruitment and retention, processing capacity, retail partnerships, organization, and cash generation — with no product-innovation or new-category pillar among them [12].

Source: December 2025 Investor Day, revenue growth drivers [13]. The consumer-panel penetration reads 11.9%; the FY2025 10-K's Circana-based figure is 10.5% [14].

The scorecard shows the engine working: buy rate up 70% and velocity up 68% since 2020, with awareness pulling away from competitors. But the two levers are not moving in step. In 2024 the company added 2.3 million households (up 20%) and pushed penetration to 10.7% [15]; on the Circana basis it then edged down to 10.5% in 2025 even as revenue grew 25% [16]. Growth has leaned increasingly on buy rate rather than new triers — a shift management flagged as early as 2024, when it conceded its 30-million-household goal (originally 2027) would likely slip to 2028, "compensated" by buy-rate gains [17]. Deepening consumption per household has more headroom than widening the base — buy rate has already grown 70% — and it is the lever most exposed when a cheaper commodity substitute appears, which is what the Category and Moat analysis shows happened in 2026.

A narrowing portfolio

At the 2020 IPO, the growth story ran on four engines: household penetration, retail expansion, foodservice, and product innovation across new categories. Five years on, three of those four have been throttled back, and the portfolio has been pruned toward core eggs.

Sources: product history and discontinuations per FY2024 Annual Report, Note 6 [18]; butter wind-down per Q1 FY2026 10-Q, Note 23 [19].

The butter exit is the sharpest turn. In February 2025 the CFO took on the added title of Butter General Manager, reported butter sales up 11% for 2024, and called the line "a crucial cornerstone in our portfolio" and "an important piece of our growth strategy to meet our long-term financial goals" [20]. Fifteen months later, in May 2026, the company elected to wind butter down entirely, citing "increased complexity in our international supply chain and more volatile economics" and a decision to "focus on our core egg categories" [21]. Butter was small — roughly $6.1M of $187.2M in first-quarter 2026 revenue, about 3% [22] — so the exit is immaterial to revenue and, management says, margin-accretive and freeing bandwidth to "accelerate distribution in the company's core egg categories" [23]. What it removes is optionality: the one adjacency management had explicitly named as a growth pillar a year earlier.

Foodservice, an IPO pillar, has drifted the same way — from about 6% of net revenue in 2023 to 4% in 2024 and 3% in 2025, even as the dollar base grew [24]. There is a genuine ambivalence in the record here: the FY2025 10-K, filed in early 2026, still lists "Expand Our Portfolio" as a stated growth strategy and speaks of "strategic bets on larger-scale opportunities" [25], while the Investor Day plan and the butter decision point the other way. The revealed strategy is a concentrated shell-egg bet; the stated one still gestures at breadth.

Capacity built ahead of demand

On the supply side, the company chose to build first and fill later. It brought a third production line online at Egg Central Station in October 2025 and installed a second Moba grading system, then began building both lines of its second plant, Vital Crossroads in Seymour, Indiana, concurrently — explicitly, in the CEO's words, "to stay ahead of demand" and out of "confidence in future demand… rather than chasing" it [26]. The farmer network expanded to more than 600 farms, adding roughly 175 in 2025 alone [27], and by early 2026 exceeded 625 [28]. Entering 2026, the CEO described supply as "unconstrained," a reversal from the demand-outrunning-capacity problem of 2024 [29].

That sequencing is the growth engine's central risk. Building fixed capacity ahead of a premium product's demand works only if the demand shows up on schedule; when it slipped in early 2026, the pre-built base turned into the mechanism of the margin collapse the Cash Conversion chapter traced. Management then reversed course on the supply build: in May 2026 it reported that "growth fell short of our publicly announced guidance," cut planned 2026 capex to $70–75M from $140–150M [30], slowed construction at Vital Crossroads, and paused development of new accelerator farms [31]. It had already begun selling the land: about 526 acres of Indiana farmland bought for accelerator farms were classified for sale in 2025, with roughly 263 acres still to go [32].

Sources: revised 2026 revenue guidance per Q1 FY2026 earnings release [33]; revised capex guidance per the release's Fiscal 2026 Outlook [34]; reset actions per Q1 FY2026 10-Q MD&A [35]; accelerator-farm land per Q1 FY2026 10-Q [36].

Slowing the build is the rational response to soft demand, and Vital Crossroads is still slated to open in 2027 [37]. But the whipsaw — build concurrently to stay ahead of demand, then within two quarters sell land and defer capacity — is itself information about how well management can forecast the demand its plan depends on.

Reading the engine

The refocusing has a defensible logic. Vital Farms' advantages — brand, the Certified Humane farmer network, retailer shelf economics — live in pasture-raised eggs, not in ghee or imported butter, and its adjacency record (egg bites, ghee, tub butter, butter) is a string of retreats. Concentrating capital and management attention on the category it leads, where household penetration is still only about 10.5% against a category near 97% [38], is a reasonable read of where the returns are.

The cost of that focus is that the $2 billion plan now has little to fall back on. Growth rests on one category's demand, driven mainly by getting existing households to spend more, and the fixed cost base has been pre-committed to it. That is precisely the configuration that produced the 2026 reset: when a cheaper commodity egg widened the price gap, there was no second category to cushion the volume miss, and a plant built ahead of demand carried its costs regardless. The bull case is operating leverage — if penetration and buy rate compound back toward 21%, the pre-built base delivers the 15–17% margin the plan promises, which is the recovery the Normalized Value analysis prices only partially. The bear case is that a single-category, demand-led plan with fixed costs already sunk is a narrower, more cyclical machine than a 21% five-year target implies.

What would change the read is observable and dated: household penetration resuming its climb toward the 30-million-household goal rather than stalling near 10–11%; buy rate holding its gains as price gaps normalize; and 2026 proving to be a one-year air pocket — a return to positive shell-egg volume growth in the second half — rather than a lower structural growth rate. If penetration stays flat and the plan continues to lean on buy rate alone, the honest conclusion is that the engine has one gear left, and the 2030 target is a demand forecast the company does not fully control.

---

Recovery or Reset

Two readings fit the same 2026 numbers. In one, this is a self-inflicted, six-to-twelve-month air pocket — a commodity-egg price collapse widened Vital Farms' shelf-price gap, trial stalled, and the fix is already in motion for a 2027 recovery. In the other, the reset is structural: a premium brand tethered to commodity feed and egg prices, now met by private-label pasture-raised, has revealed unit economics that only work at the top of the cycle. The evidence does not yet settle it. This chapter steelmans both, sizes the solvency floor a margin-of-safety buyer needs, and sets the dated signposts that will separate the two.

Where the reset landed

Fiscal 2025 was the peak of the cycle. Net revenue reached $759 million, operating margin hit 11.6%, and adjusted EBITDA topped $100 million for the first time at $114.0 million, or 15.0% of net revenue [1]. In February 2026 management guided fiscal 2026 to $900–920 million of revenue, $105–115 million of adjusted EBITDA, and $140–150 million of capex, and reaffirmed the $2 billion-by-2030 target [2]. Ten weeks later, on the May 2026 call, that guide was cut to $775–800 million of revenue and $0–10 million of adjusted EBITDA — near-breakeven at the operating line — with the CEO framing it as "a reset of the year, not a reset of ambition" [3].

Source: FY2024/FY2025 actuals, Q4 FY2025 earnings release [4]; FY2026 guide midpoint, Q1 FY2026 earnings release [5].

The first-quarter print showed the mechanism. Revenue still grew 15.4% to $187.2 million, but gross margin fell to 28.3% from 38.5% a year earlier as an oversupply of eggs was dumped into the low-price breaker channel — a mix shift that alone cut gross profit by an estimated $4.9 million — and adjusted EBITDA margin dropped to 2.7% [6]. The sell-side repriced accordingly. Consensus fiscal-2026 EPS, which stood near $1.10 in April, is now a loss of roughly $0.42; fiscal-2027 EPS was cut from about $1.39 to $0.44.

Source: consensus estimates, trailing 90 days (as of July 2026).

The recovery case

The bull case begins with a category that is still early. Household penetration is 10.5% against shell-egg category penetration of about 97.3%, and the U.S. pasture-raised retail market — roughly $1.3 billion of a $15.4 billion shell-egg category in 2025 — has compounded at a 37.5% CAGR since 2021 [7]. Even through the 2026 disruption the shift kept going: outdoor-access eggs grew from 8% of category volume in 2023 to 15% so far in 2026, and year-to-date outdoor-access volume was up 32% against 4% for mainstream eggs, despite commodity eggs at their cheapest in years [8]. Vital remains the number-one or number-two branded egg by dollar sales at nine of its ten largest customers [9].

Read this way, 2026 is a pricing problem, not a demand problem. Existing consumers stayed loyal — buy rate per retained household actually rose about 2% — while the rate of new households trying the brand for the first time fell from more than 55% in 2024–2025 to 50% in the first quarter, which management attributes to a price gap that reached levels the brand could not sustain [10]. The proposed fix is narrow and testable: close price gaps geography by geography. At one top-ten customer, cutting the gap versus competing premium eggs from about 35% to 25% lifted volume 18% within two weeks [11].

The cost relief is back-end-loaded but concrete. Management is right-sizing staffing at Egg Central Station (roughly $4 million), cut about 10% of non-plant headcount, is targeting feed (roughly $125 million of COGS), and is exiting butter for a 150–200 basis-point gross-margin benefit from 2027 [12]. Capacity is already in the ground — Egg Central Station alone carries over $1 billion of revenue capacity — so the next leg of growth is low-capex, and management guides gross margin back to 30% by late in the fourth quarter of 2026 and adjusted EBITDA margin back to double digits in 2027 [13]. With no term debt and capex halved to preserve cash, the setup is the near-term-pain, later-gain shape a patient buyer looks for.

The structural-reset case

The counter-case is that the pain is not transient because its source is not transient. Vital buys eggs from its contracted farmers regardless of the retail sales environment, so when commodity eggs collapse — breaker prices touched $0.10 per dozen in the quarter — the brand's price gap widens mechanically, and the oversupply spills into loss-making channels [14]. This is the commodity exposure a buyer who dislikes commodity businesses would flag: the premium is real, but it floats on a commodity spread the company does not control. If cheap commodity eggs persist, the gap — and the trial slowdown it caused — persists with them.

The growth engine was already softening before the shock. Household penetration edged down from 10.7% in 2024 to 10.5% in 2025 even as revenue grew, the 30-million-household goal slipped from 2027 to 2028, and the plan narrowed to a single lever after every adjacency was pruned (the detail is in The Growth Engine). On the competitive flank, private-label pasture-raised has begun to encroach on the premium (Category and Moat); management's framing is that private label "is expanding the pasture raised category but not sourcing its growth from branded products" [15] — a benign reading only if the price gap it opens does not keep pulling triers away.

Most important for this reader, the "later gain" has never reliably shown up as owner cash. Across fiscal 2018–2025, Vital converted only about six cents of free cash flow per dollar of net income and was FCF-negative in three of eight years, including 2025 (Cash Conversion); 2026 will be negative again. The 2027 recovery is a guidance line, not a result — and it comes from a management team that cut the same year's guide twice in ten weeks and missed the first-quarter consensus by roughly 150%. Consensus, notably, does not underwrite a full heal: fiscal-2027 EPS of $0.44 sits well below the $1.44 of fiscal 2025.

The tension table

Each row is a fact both sides accept; the disagreement is what it means.

Sources: FY2025 10-K [16]; Q1 FY2026 earnings call [17] [18]; Q1 FY2026 10-Q [19].

Solvency and the margin of safety

For a buyer who never touches a company that could go bankrupt, the balance sheet is the first screen, and it clears the near-term bar. At the end of the first quarter Vital held $51.4 million of cash and marketable securities with no debt outstanding, and it has a $60 million undrawn revolver behind that — roughly $111 million of liquidity against a cash burn the company expects to fund internally [20]. Book equity was $351 million at year-end 2025 with negligible goodwill, a real if eroding floor of about $8 per share, and net cash is roughly $1.20 per share.

Source: Q1 FY2026 earnings call and balance sheet [21]; book equity derived from the FY2025 10-K balance sheet.

The caution is that the cushion is thinning and the covenant math tightens as it does. Cash and securities more than halved in a single quarter, from $113.4 million at year-end to $51.4 million, and management confirmed it "will start using the revolver," with two financial covenants in view — a net-leverage ratio of 3.5x and a fixed-charge-coverage ratio of 1.35x [22]. Because EBITDA is the denominator of a leverage covenant, a 3.5x ceiling permits very little borrowing while adjusted EBITDA sits near zero — the constraint is self-tightening in exactly the year the company needs the facility. The 10-Q also flags $35–50 million of supply-control costs over the next twelve months, partly cash outflows to farmers to curb production [23].

Against that backdrop, the capital-allocation choice is the governance flag (Ownership and Control). The board authorized a $100 million buyback in February 2026 and spent $20 million in the first quarter at an average price of $19.97 — well above the roughly $13 the shares trade at today — while the business was turning cash-negative and preparing to draw its revolver [24]. Management does hold quarterly calls and answers directly, but the founder is no longer the one giving updates, and buying stock at $20 into a cash squeeze is the kind of decision this reader weighs against the solvency screen.

On price, the stock is cheap against peak earnings and dear against trough earnings — the same fact both sides cite. At about $12.95, roughly 9x fiscal-2025 EPS of $1.44 and about 4.4x fiscal-2025 adjusted EBITDA of $114 million, it looks inexpensive; on fiscal-2026's near-breakeven EBITDA and a consensus loss, no multiple is meaningful. The margin of safety therefore rests on normalized earnings, and the reconciliation of what the price implies is in Normalized Value: the current quote is consistent with a partial heal to a mid-single-digit margin, not a return to 15%.

What to watch

The two readings resolve on a short list of dated, checkable markers over the next four quarters.

Sources: Q1 FY2026 earnings call [25] [26]; consensus estimates and earnings calendar (next report Aug 6, 2026).

Reconciliation

The recovery and the reset are not opposing forecasts so much as opposing views of one variable: whether Vital's shelf-price gap is a cyclical artifact of unusually cheap commodity eggs or a structural feature of selling a premium product into a commodity spread now shadowed by private label. The company's own plan is a clean test of it — narrow the gap, restore volume in the third and fourth quarters, carry cost savings into 2027 — and the plan prints on a schedule, quarter by quarter, in the markers above.

For a margin-of-safety buyer the asymmetry is specific. The solvency floor is real and checkable now: no term debt, roughly $111 million of liquidity, a book-value floor near $8. The earnings floor is not yet visible, because 2026 is guided to near-breakeven and 2027 is a promise consensus only partly believes. The near-term-pain, later-gain shape is genuinely present; what remains unproven is that the later gain arrives as owner cash rather than as another year of reinvestment — the question the whole report has circled. The next two prints, in August and November 2026, are the first place that answer becomes a number.

---

Supply and Biosecurity

Vital Farms' physical supply chain splits its risk in two opposite directions. On the disease side it is deliberately dispersed — more than 600 small pasture farms, so a single avian-influenza hit is a fraction of a percent of laying capacity, and no Vital farm was lost to the virus in 2025 [1] while the U.S. industry culled roughly 79 million hens across 2024 and 2025 [2]. On the processing and cost side it is concentrated — nearly all eggs pass through one Springfield facility, and gross margin is tethered to corn and soy.

Two geometries of risk

Outdoor access is the entire premise of the brand — Certified Humane rules require at least 108 square feet of pasture per hen and daily time outside — and it is also the feature that, in principle, raises exposure to a virus carried by wild birds. That tension is the natural first question for anyone weighing an egg producer whose hens are, by design, not sealed indoors. The evidence in the filings resolves it in an unexpected direction: the pasture model is more resilient to a flock-level disease event than the concentrated cage industry, because the same standard that puts hens outside also forces production across hundreds of small, physically separated sites.

The reader-relevant distinction is between two kinds of risk that this chapter treats separately. Flock risk — losing birds to disease — is spread thin. Facility and input risk — losing the one plant that washes and packs the eggs, or absorbing a swing in feed cost — is not. A margin-of-safety buyer who screens out businesses that could fail should weigh the second far more heavily than the first.

Distribution as biosecurity

Vital contracts with a network that has grown from about 275 farms in 2021 to more than 425 in 2024 and over 600 in 2025 [3]. Management's own framing of why that matters dates back to the first HPAI wave: because the birds sit on many small sites rather than a few large ones, a single infected farm is "less than half a percent of our productive capacity," and the model has "resilience simply in … not having a small number of very concentrated farm sites, which once affected, affects all of the hens on that site" [4].

The record since then supports the claim more than it undercuts it. Vital experienced HPAI at exactly one farm in fiscal 2024 and at none in fiscal 2025 — through the worst two years of avian influenza the U.S. egg industry has seen [5]. The contrast with the concentrated model is stark. Cal-Maine, the largest U.S. shell-egg producer, lost approximately 3.1 million laying hens and 577,000 pullets from HPAI at just two of its facilities in fiscal 2024, with operations at both sites halted until they could be cleared and repopulated [6]. A single-site loss at a concentrated producer exceeds the entire bird count on any one Vital farm by orders of magnitude.

Sources: Vital Farms FY2025 10-K, MD&A [7] and Q4 FY2021 call [8]; Cal-Maine FY2024 10-K [9].

The industry backdrop shows what Vital avoided. Cal-Maine's filings record roughly 40.2 million commercial layer hens and pullets depopulated nationally in calendar 2024 and a further 39.0 million through May 2025, pulling the U.S. table-egg flock down to about 285.5 million hens from a five-year average near 313 million [10]. That supply destruction is what drove commodity egg prices to record highs and back down — the same price swing that widened Vital's shelf-price gap in 2026 (Cash Conversion). The disease that most threatens the industry has, so far, done its damage to Vital indirectly through the commodity price, not directly through its own flock.

The counter-fact belongs in the same breath. Distribution lowers the odds of a total loss; it does not make the network immune, and a new disease has appeared alongside HPAI. Egg drop syndrome (EDS) hit nine Vital farms in fiscal 2024 and twelve in fiscal 2025; the company has begun procuring vaccinations but states plainly it "may not be able to obtain enough vaccinations to treat all of the flocks in our network" [11]. A widespread outbreak that moved through the Pasture Belt, or a demand shock from the mere perception of disease, would still hurt — distribution protects the asset base, not the market. Cal-Maine, for its part, has spent more than $75 million on biosecurity since 2015, a reminder that the concentrated model defends itself with capital where the pasture model defends itself with geography [12].

One facility, one region

Where the flock is dispersed, the processing is not. Almost every Vital egg is washed and packed at a single plant — Egg Central Station in Springfield, Missouri, roughly 153,000 square feet after its 2022 expansion [13] and capable of packing more than 7.5 million eggs a day [14]. The company names the exposure directly: "A substantial amount of our shell egg processing occurs at our Egg Central Station … Any damage or disruption at this facility … may harm our business" [15]. A separate risk factor sizes the geographic dimension: operations are "geographically consolidated," and "a major tornado or other natural disaster or extreme weather event within the regions in which we operate could seriously disrupt our entire business" [16]. Springfield sits in a part of the country where tornadoes are a routine hazard, and the entire farm network is clustered in the same weather-defined Pasture Belt.

This is the concentration a bankruptcy-averse buyer should weigh most. A prolonged loss of the one plant would strand the eggs the company is contractually bound to buy from its farmers regardless of whether it can sell them [17], turning a distributed supply advantage into a single-point liability at the neck of the funnel. It is the mirror image of the disease picture: many farms, one throat.

The mitigation is underway and is the item that most changes this risk. Vital broke ground in 2025 on Vital Crossroads, a second washing-and-packing facility with onsite cold storage in Seymour, Indiana, expected to be fully operational in 2027 [18]. Read alongside The Growth Engine, the second plant is not only capacity for the $2 billion ambition — it is the end of single-facility dependence, moving Vital from one processing site to two in a different state and a different weather system. The qualifier is timing: the plant's construction was slowed in the 2026 pull-back, so the de-risking arrives on a 2027 schedule that management has already shown it will flex to protect cash. Until it opens, the single-facility exposure stands.

The feed tether

The cost side is where Vital most resembles a commodity business. The price it pays contracted farmers for eggs is reset quarterly for changes in feed cost, so movements in corn and soybean meal flow through to Vital's gross margin by contract design; the farmer funds the birds and feed as working capital, but the input-price risk lands on Vital [19]. The filing quantifies the sensitivity: a hypothetical 10% move in the weighted-average cost of these ingredients — primarily corn and soy — would have changed fiscal-2025 cost of goods sold by approximately $12.9 million, with packaging adding a further $5.2 million per 10% move [20].

Source: FY2025 10-K, Item 7A market-risk disclosures [21]; percentage of gross profit derived from FY2025 gross profit of $285.7M.

Sized against the business, the input tether is real but not, on its own, the dominant swing factor. Against FY2025 gross profit of $285.7 million, a 10% feed move is about 4.5% of gross profit, and feed plus packaging together about 6.3%. Vital runs commodity derivative contracts on conventional feed to blunt part of this [22]. The more damaging commodity exposure sits on the other side of the model: not the cost of feed going in, but the price of commodity eggs on the shelf next to Vital's, which is what compressed velocities and margin in 2026 (Recovery or Reset). Vital is a commodity business at both ends, but the ends are not the same size — the demand-side price gap has moved earnings far more than the feed line has.

What it means for a margin-of-safety buyer

The net read is that the physical supply chain is a genuine, under-credited strength on disease and a real but shrinking liability on concentration. The distributed farm network has done in practice what management said it would — carried Vital through the worst avian-influenza years with a single lost farm while competitors depopulated millions of birds — and that is a structural feature, not luck, rooted in the same outdoor standard that defines the brand. The offsetting exposures are the single Springfield plant in tornado country and the feed tether, both of which are bounded: the plant risk is being halved by a second facility on a 2027 timeline, and the feed risk is sized at roughly 4.5% of gross profit per 10% move and partly hedged.

The evidence points to a supply chain that lowers, rather than raises, the odds of the kind of catastrophic operational failure a bankruptcy-averse investor screens for — the flock cannot be wiped out at one site, the balance sheet carries no processing-plant debt, and the second facility removes the last obvious single point of failure. The main risk to that read is a low-probability, high-severity event the distribution does not cover: a Pasture-Belt-wide disease sweep, a new pathogen like EDS outrunning the vaccine supply, or a natural disaster striking Springfield before Vital Crossroads opens. What would change the read is a widening EDS footprint across the network in 2026–2027, or a slip in the Vital Crossroads schedule that leaves single-facility dependence in place longer than the 2027 target implies.

---

Channel Concentration

Vital's brand pulls consumers, but its route to them runs through a thin layer of intermediaries. One distributor — UNFI, Whole Foods' primary distributor — has carried between 22% and 26% of net revenue every year since 2022, on contracts with no minimum-purchase commitment [1]. Retailer concentration has eased since 2019; the distributor chokepoint has not. The brand's growing shelf power is the offset.

The path to the shelf

Vital does not sell most of its eggs directly to shoppers or, for a large share of volume, even directly to the grocers who stock them. It runs a broker-distributor-retailer network: brokers represent the products, distributors buy, store and deliver them, and retailers sell them on [1]. The origin of that structure is the company's origin: less than a year after its first farmers'-market sales, Vital's eggs were "discovered by Whole Foods" [8], and Whole Foods has been the single largest destination for its products ever since.

That history shaped a concentrated go-to-market. The majority of natural-channel customers are served through food distributors, chiefly UNFI, which "purchase, store, sell and deliver" the products to retailers [1]. A short list of large retail customers — Whole Foods and Kroger foremost — sits at the other end. The result is a business whose consumer brand is broad but whose commercial counterparties are few.

Sources: FY2025 Annual Report (Form 10-K), UNFI and foodservice shares [1]; Whole Foods and Kroger retail-sales shares [2]; foodservice share [5].

One distributor, a quarter of revenue

UNFI is the largest single dependency in the model, and it is larger than any retailer. It accounted for approximately 25%, 24% and 22% of net revenue in fiscal 2023, 2024 and 2025 [1]. The share has drifted down over three years, but it sat at roughly a quarter of the company's revenue at the end of 2025 — a larger slice than Whole Foods (20% of retail sales), the retailer UNFI mainly serves, because UNFI also carries Vital's products to much of the rest of the natural channel [2].

Sources: FY2021 10-K, FY2019–FY2021 shares [3]; FY2023 10-K, FY2022 share [6]; FY2025 10-K, FY2023–FY2025 shares [1].

The dependency was more diffuse at the IPO than it is now. In 2019, three distributors each cleared the 10% disclosure threshold — UNFI at 35% of net revenue, US Foods at less than 10%, KeHE at 11% — with the mix shifting sharply year to year as Whole Foods changed its primary distributor between UNFI and US Foods [3]. By 2025 only UNFI still cleared the threshold; KeHE and US Foods had fallen below 10% and out of the disclosure. The "core number of distributors" Vital says will carry a substantial portion of its sales has, in practice, narrowed toward one [1].

Source: FY2021 Annual Report (Form 10-K), Risk Factors — distributor shares of net revenue; US Foods FY2019 disclosed as "less than 10%" (shown blank) [3].

Two features of that arrangement matter for revenue durability. First, there is no contractual floor: Vital "do[es] not have short-term or long-term commitments or minimum purchase volumes" in its distributor contracts, and distributors — selected by the retailers, not by Vital — "are able to decide on the products carried, and they may limit the products available" [1]. Second, the counterparty is itself a thin-margin, leveraged business: UNFI reported roughly $31.8 billion of fiscal-2025 revenue but a fourth-quarter net loss and net debt near $1.8 billion, at about 3.3x adjusted EBITDA, per its own fiscal-2025 results. A distributor that routes a quarter of Vital's revenue and operates on grocery-distribution margins is a concentration a bankruptcy-averse buyer weighs on both sides — Vital's dependence on it, and its own balance sheet.

Customer concentration has eased

Against the distributor chokepoint, the retailer side of the ledger has genuinely improved. Whole Foods fell from about 30% of retail sales in 2019 to 20% in 2025; Kroger has held near 11–12% throughout [3] [2]. The clearest measure of diversification is the channel mix: natural-channel retailers, led by Whole Foods and Sprouts, were 51% of retail dollar sales in 2019 and 38% in 2025, as the mainstream channel — Albertsons, Kroger, Publix, Target, Walmart — grew to 62% [4] [5].

Sources: FY2021 10-K, FY2019–FY2021 channel mix [4]; FY2025 10-K, FY2023–FY2025 channel mix [5]; FY2020 and FY2022 mainstream shares derived as the complement of the disclosed natural-channel share.

The mix shift also loosens the distributor grip, because the two channels reach the shelf differently. Natural-channel volume runs through distributors like UNFI; mainstream customers such as Kroger are served more directly, as Vital's own "largest direct retail customer" [3]. Growing the mainstream channel therefore both diversifies the customer base and shortens the path to a larger share of it — which is part of why UNFI's revenue share has fallen even as absolute sales through it rose.

The brand's leverage over the channel

The channel is concentrated, but the leverage is not one-way. A brand that shoppers ask for by name is one a retailer wants on the shelf, and Vital's recent commercial wins read as a brand negotiating from strength rather than a supplier at the mercy of its distributors. On the first-quarter 2026 call, management described securing at least a 50% increase in total distribution points with a top-three customer, being assigned the "category captain" role for eggs at a banner of another top-three customer, and — most directly relevant here — negotiating "direct distribution instead of going through a distributor with a top 10 customer" [7].

That last move is the channel dynamic in miniature: as Vital gains scale and shelf pull, it can bypass the intermediary layer for its largest accounts, capturing margin and control that the broker-distributor structure otherwise cedes. The same call showed the flip side — the brand's pricing is set at the retailer level, geography by geography, and a price gap that widened too far at "a top 10 customer" cut volumes until Vital narrowed it, after which volumes rose 18% in two weeks [7]. Shelf power and shelf exposure are the same relationship viewed from two sides.

The read and what would change it

The channel is a real concentration but a manageable one, and it is moving in the right direction on the retailer axis while staying stubborn on the distributor axis. Customer diversification is genuine — Whole Foods down to 20% of retail sales, the mainstream channel now nearly two-thirds of the base — and the brand's shelf pull is strong enough to win category-captain status and disintermediate distributors for its largest accounts. The offsetting fact is UNFI: roughly a quarter of net revenue still flows through one thin-margin, leveraged distributor on contracts with no minimum-purchase floor, and that distributor can limit which products reach the shelf [1]. The brand pulls consumers; whether that pull converts into durable cash depends partly on who controls the shelf between them.

What would change the read in either direction is observable. A continued decline in UNFI's revenue share, more direct-distribution conversions like the top-ten win, and further mainstream-channel growth would confirm the dependency is being engineered down. A reversal — UNFI's share climbing back toward its 2022 peak, a distributor delisting SKUs, or financial distress at UNFI itself forcing a disorderly transition — would show the chokepoint still binds. For a business already tethered to commodity egg economics (Cash Conversion) and defending a brand-and-network moat rather than a structural one (Category and Moat), the channel is a third place the premium either holds or gives way.